Biochemical Recurrence in Pathologic T3-4 Prostate Cancer: Indications for Adjuvant Radiotherapy.
[BACKGROUND] The study aimed to identify potential candidates for adjuvant radiotherapy by stratifying patients with locally advanced prostate cancer based on their biochemical recurrence (BCR) risk.
- p-value p < 0.001
- 95% CI 1.51-2.93
- 추적기간 60 months
APA
Ozawa Y, Sharma R, et al. (2025). Biochemical Recurrence in Pathologic T3-4 Prostate Cancer: Indications for Adjuvant Radiotherapy.. Annals of surgical oncology, 32(13), 10261-10271. https://doi.org/10.1245/s10434-025-17745-4
MLA
Ozawa Y, et al.. "Biochemical Recurrence in Pathologic T3-4 Prostate Cancer: Indications for Adjuvant Radiotherapy.." Annals of surgical oncology, vol. 32, no. 13, 2025, pp. 10261-10271.
PMID
40659894
Abstract
[BACKGROUND] The study aimed to identify potential candidates for adjuvant radiotherapy by stratifying patients with locally advanced prostate cancer based on their biochemical recurrence (BCR) risk.
[METHODS] This study analyzed data from 3536 men with pT3-4 disease who achieved undetectable prostate-specific antigen (PSA) levels after robot-assisted radical prostatectomy between 2008 and 2023. Kaplan-Meier curves and log-rank tests were used to compare BCR risk across pathologic T (pT) stages. The study also evaluated associations between BCR and other adverse pathologic features, including pathologic grade group (GG), pathologic N (pN) stage, positive surgical margin, perineural invasion, lymphovascular invasion, tumor diameter, and tumor percentage involvement. A multivariable Cox regression was used to adjust for potential confounders, including age, race, Charlson Comorbidity Index, and PSA at biopsy.
[RESULTS] The median follow-up period was 60 months (interquartile range [IQR], 24-84 months), with BCR occurring in 852 patients. The patients with pT3b and pT4 disease had higher BCR risk (hazard ratio [HR], 2.54; 95% confidence interval [CI], 2.19-2.94) than those with pT3a disease (HR, 2.10; 95% CI, 1.51-2.93). In the multivariable analysis, the independent predictors for BCR were GG3-5, pT3b, lymphovascular invasion, positive surgical margin, and tumor diameter, with GG5 having the strongest prognostic significance. The combination of GG3-5 and the cumulative number of these adverse features further stratified BCR risk (p < 0.001).
[CONCLUSIONS] The study demonstrated that patients with GG5 locally advanced disease and multiple adverse pathologic features have the highest BCR risk after achieving undetectable PSA levels. These patients are potential candidates for adjuvant radiotherapy and should receive comprehensive counseling regarding its potential benefits. Prospective studies are warranted to optimize patient selection for adjuvant therapy.
[METHODS] This study analyzed data from 3536 men with pT3-4 disease who achieved undetectable prostate-specific antigen (PSA) levels after robot-assisted radical prostatectomy between 2008 and 2023. Kaplan-Meier curves and log-rank tests were used to compare BCR risk across pathologic T (pT) stages. The study also evaluated associations between BCR and other adverse pathologic features, including pathologic grade group (GG), pathologic N (pN) stage, positive surgical margin, perineural invasion, lymphovascular invasion, tumor diameter, and tumor percentage involvement. A multivariable Cox regression was used to adjust for potential confounders, including age, race, Charlson Comorbidity Index, and PSA at biopsy.
[RESULTS] The median follow-up period was 60 months (interquartile range [IQR], 24-84 months), with BCR occurring in 852 patients. The patients with pT3b and pT4 disease had higher BCR risk (hazard ratio [HR], 2.54; 95% confidence interval [CI], 2.19-2.94) than those with pT3a disease (HR, 2.10; 95% CI, 1.51-2.93). In the multivariable analysis, the independent predictors for BCR were GG3-5, pT3b, lymphovascular invasion, positive surgical margin, and tumor diameter, with GG5 having the strongest prognostic significance. The combination of GG3-5 and the cumulative number of these adverse features further stratified BCR risk (p < 0.001).
[CONCLUSIONS] The study demonstrated that patients with GG5 locally advanced disease and multiple adverse pathologic features have the highest BCR risk after achieving undetectable PSA levels. These patients are potential candidates for adjuvant radiotherapy and should receive comprehensive counseling regarding its potential benefits. Prospective studies are warranted to optimize patient selection for adjuvant therapy.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Aged; Follow-Up Studies; Neoplasm Staging; Prognosis; Survival Rate; Retrospective Studies; Neoplasm Grading; Neoplasm Invasiveness
같은 제1저자의 인용 많은 논문 (5)
- Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
- Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates.
- Risk factors for seminal vesicle invasion at radical prostatectomy.
- Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy.
- Cell Cycle Progression Score Identifies Biopsy-Undetected Grade Group 5 Prostate Cancer.